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Abstract
Breast cancer research is hampered by difﬁculties in obtaining and studying primary human breast tissue,
and by the lack of in vivo preclinical models that reﬂect patient tumor biology accurately. To overcome these
limitations, we propagated a cohort of human breast tumors grown in the epithelium-free mammary fat pad of
severe combined immunodeﬁcient (SCID)/Beige and nonobese diabetic (NOD)/SCID/IL-2g-receptor null
(NSG) mice under a series of transplant conditions. Both models yielded stably transplantable xenografts at
comparably high rates (!21% and!19%, respectively). Of the conditions tested, xenograft take ratewas highest
in the presence of a low-dose estradiol pellet. Overall, 32 stably transplantable xenograft lines were established,
representing 25 unique patients. Most tumors yielding xenografts were "triple-negative" [estrogen receptor
(ER)"progesterone receptor (PR)"HER2þ; n ¼ 19]. However, we established lines from 3 ER"PR"HER2þ
tumors, one ERþPR"HER2", one ERþPRþHER2", and one "triple-positive" (ERþPRþHER2þ) tumor. Serially
passaged xenografts show biologic consistency with the tumor of origin, are phenotypically stable across
multiple transplant generations at the histologic, transcriptomic, proteomic, and genomic levels, and show
comparable treatment responses as those observed clinically. Xenografts representing 12 patients, including 2
ERþ lines, showed metastasis to the mouse lung. These models thus serve as a renewable, quality-controlled
tissue resource for preclinical studies investigating treatment response and metastasis. Cancer Res; 73(15);
4885–97. !2013 AACR.
Introduction
In translational breast cancer research, our ability to eval-
uate clinical responses of human tumors to new therapeutic
agents is restricted experimentally. For example, we cannot
evaluate the clinical response of a single treatment-na€"ve
tumor to multiple candidate therapeutics. Furthermore, the
number of in vivo preclinical human tumor models currently
available remains limited, thus precluding conduct of xeno-
graft-based "mouse clinical trials," reﬂecting the heterogeneity
of human tumors using candidate therapeutic agents. These
limitations severely compromise our ability to develop and test
novel therapeutics, and to predict the best course of treatment
for a given tumor subtype, andmore importantly, an individual
patient with breast cancer.
Historically, in vivo experimental therapeutic research has
relied on either genetically engineeredmousemodels, or "xeno-
graft" transplantation models, in which established human
cancer cell lines are transplanted into immunocompromised
hostmice (1–3). However, whilemousemodelsmutant for TP53
do show a high degree of heterogeneity, genetically engineered
animal models do not fully recapitulate the full spectrum of
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human breast cancers (4). Similarly, a cell line represents only a
single tumor type, and indeed only a single patient. Further-
more, most available cell lines have been maintained in culture
for years, or decades, and it has been debatedwhether these cell
lines still accurately reﬂect the biologic characteristics of the
tumor of origin (5–7).
Early attempts to use primary breast cancer tissue xenografts
[also known as patient-derived xenografts (PDX) models, or
"tumorgrafts"] as experimentalmodelsmetwith limited success
(1, 2, 5, 6, 8–12),with typical rates of stable transplantationbeing
10% or less. Most of these attempts used athymic (nude) or
nonobese diabetic/severe combined immunodeﬁcient (NOD/
SCID) mice, which lack B- and T-cell function but retain innate
cellular immunity [natural killer (NK) cells, macrophages etc.]
frequently leading to elimination of tumor cells over time (13,
14). A vast majority of the stable xenografts produced have not
expressed the estrogen receptor (ER)", but ERþ xenografts have
recently begun to be reported (9, 11, 12, 15).
In a recent report, the efﬁciency of transplantation using
normal human mammary epithelial cells (from reduction
mammoplasty) was increased by "humanizing" the mammary
fat pad of NOD/SCID mice via introducing an immortalized
human ﬁbroblast cell line, derived from a normal donor, into
the mammary fat pad before transplantation (10). The inﬂu-
ence of these human ﬁbroblasts on the growth of patient-
derived breast cancerwas not tested. In any case, because these
ﬁbroblasts were derived from a normal patient rather than
from the patient-matched tumors, the presence of such ﬁbro-
blasts may alter tumor biology signiﬁcantly.
We sought to circumvent some of these limitations by
propagating human tumors as xenografts in SCID/Beige
(SCID/Bg) immunocompromised mice, which were known to
accept transplants of hematopoetic malignancies with higher
efﬁciency than traditional immunocompromised models, and
had not been used previously to establish breast cancer
xenografts. SCID/Bg mice lack B-cell, T-cell, and NK cell
function entirely, but show enhancedmacrophage populations
relative to wild-type mice (13, 14). Macrophages are required
for mammary gland growth (16, 17) and immature myeloid
cells of the macrophage lineage were recently shown to pro-
mote tumor invasion and metastasis (18). Three different
transplantation conditions were compared and the optimal
transplant condition also used to evaluate outgrowth rates in
NOD/SCID/IL-2g-receptor null (NSG) immunocompromised
mice. Resulting stably transplantable xenografts were charac-
terized with respect to expression of clinically relevant bio-
markers and gene expression patterns (mRNA and protein),
and a subset of patient/xenograft treatment responses, to lay
the foundation for their use as preclinical models for breast
cancer research.
Materials and Methods
Patient recruitment
Patients with breast cancer were recruited from clinics in
the Baylor College of Medicine (BCM) Breast Center (Houston,
TX) and Ben Taub General Hospital (Houston, TX) under
Institutional Review Board-approved protocols. Most patients
received initial core-needle biopsies at the time of diagnosis
and again either during or after treatment. Surgical samples
were also obtained whenever possible.
Establishment of xenografts
The study design is outlined in Supplementary Fig. S1. All
mice were maintained and treated in accordance with the NIH
Guide for the Care and Use of Experimental Animals with
approval from the BCM Institutional Animal Care and Use
Committee. A detailed surgical protocol was published else-
where (19).
Pretreatment biopsy and posttreatment surgical speci-
mens were received within an hour after excision. For frag-
ment transplantation, samples were minced into approxi-
mately 1 mm3 fragments and transplanted directly into
epithelium-free "cleared" fat pads (20) of recipient SCID/Bg
(Charles River Laboratories), or NSG mice (Jackson Labora-
tories; n¼ 2 per patient). Transplants were conducted under
the following conditions: condition 1: unmanipulated host
mice, condition 2: 17b-Estradiol supplementation (60-day
release, 0.36 mg/pellet, Innovative Research of America,
Cat.# SE-121), or condition 3: 17b-Estradiol supplementation
with inclusion of 5 % 104 immortalized normal human
ﬁbroblasts [passages 35–41; 1:1 unirradiated:irradiated cells
(4 Gy), as described previously (10); ﬁbroblasts generously
provided by Dr. Charlotte Kuperwasser, Tufts University,
Boston, MA). Mice were palpated weekly and tumor growth
measured using calipers. Conditions found to be optimal for
SCID/Bgmice were then tested using NSGmice (condition 4).
We were also able to obtain a few samples from either
pleural effusion or metastatic ascites. Fluid was centrifuged
and cells resuspended in a volume of 10 to 50 mL, and injected
into the cleared mammary fat pad using a Hamilton syringe.
Xenografts derived from such samples were not included in the
statistical analyses, but are included here for completeness of
the collection.
Regardless of the source of tumor cells, when primary out-
growths reached 10 mm in diameter, or if glands were sus-
pected of carrying small primary outgrowths, fragments were
retransplanted into new hosts (n ¼ 3–4) as secondary xeno-
grafts. If no overt tumor formation was observed by 30 weeks,
glands were harvested and processed for histologic evaluation.
Primary outgrowth take was deﬁned as a surviving tissue
fragment more than 1 mm in diameter and shown to be
proliferative (Ki67 positivity). A xenograft line was deﬁned as
stable upon growth at transplant generation 3 (TG3).
Statistical analysis of clinical characteristics, biomarker
expression, and outgrowth potential
The overall primary outgrowth and stable xenograft take
rates were computed for each transplantation condition
(Table 1) and compared using logistic regression. Clinical
characteristics were summarized and compared across 4
different transplantation conditions using Fisher's exact test.
Within each transplantation condition, primary outgrowth as
well as stable take rate was compared by clinical character-
istics using Fisher's exact test (Supplementary Table S1). There
were a few patient samples appearing in both transplantation
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conditions 2 and 3. We conducted a McNemar test to examine
those overlapping samples and did not observe any signiﬁcant
difference. Thus, we analyzed the data as independent samples
for different transplantation conditions.
Xenograft characterization
Xenografts were validated as unique by short tandem repeat
(STR) DNA ﬁngerprinting using the AmpF_STR Identiﬁler kit
according to manufacturer's instructions (Applied Biosystems
Cat.# 4322288). The STR proﬁles were compared with known
American Type Culture Collection (ATCC) ﬁngerprints (ATCC.
org) and to the Cell Line Integrated Molecular Authentication
database version 0.1.200808 (http://bioinformatics.istge.it/
clima/; ref. 21). The STR proﬁles of all xenograft lines were
unique (Supplementary Table S2).
Histologic evaluation of xenografts
Transplanted glands/tumors were ﬁxed in 10% neutral
buffered formalin, parafﬁn embedded, and hematoxylin–eosin
(H&E) stained. Outgrowths were analyzed by immunohis-
tochemistry for stability of expression of clinically-relevant
biomarkers (ERa, PR, HER2, Ki67; ERa, Novocastra Laborato-
ries Ltd., Cat.# NCL-ER-6F11; PR, DAKO, Cat.# M3568; HER2,
NeoMarkers, Lab Vision Corporation, Cat.# RM-9103; Ki67,
DAKO, Cat.# M7240) with positive controls. Additional bio-
markers included human cytokeratin 19 (CK19; NeoMarkers,
Lab Vision Corporation, Cat.# MS-198-P, 1:400), Cytokeratin
5/6 (CK5/6; DAKO, Cat.# M7237 at a 1:100 dilution), EGF
receptor (EGFR; pharmDx Kit, DAKO, Cat.# K1492, ready to
use), and TP53 (Vector, Cat.# VP-P958, 1:1,000 dilutions).
Biomarker expression patterns were compared with the tumor
of origin whenever possible, or with the clinical pathology
report (Table 2 and Supplementary Table S3).
Intrinsic subtype analysis
Xenografts were proﬁled as described previously using 244K
human oligo microarrays (Agilent Technologies; ref. 22). The
probes or genes for all analyses were ﬁltered by requiring the
lowest normalized intensity values in both sample and control
to be more than 10. The normalized log2 ratios (Cy5 sample/
Cy3 control) of probes mapping to the same gene (Entrez ID as
deﬁned by the manufacturer) were averaged to generate
independent expression estimates. For Cy3 controls, we used
Stratagene Human Universal Reference (23) enriched with
equal amounts of RNA from the MCF7 and ME16C cell lines.
Genes were median-centered and samples were standardized
to zero mean and unit variance. To combine the BCM xeno-
graft gene expression data with the UNC337 dataset, we
estimated the technical bias from a subset of samples (n ¼
35) of the UNC337 dataset that were also proﬁled on the 244K
platform. Intrinsic subtype classiﬁcation was conducted in the
combined BCM xenograft and UNC337 dataset using the
PAM50 algorithm (24) and the 9-Cell Line Claudin-low Pre-
dictor (25; Table 2 and Supplementary Table S3). All Agilent
microarray data are available in the University of North Car-
olina (UNC; Chapel Hill, NC) Microarray Database (https://
genome.unc.edu/) and have been deposited in the Gene
Expression Omnibus (GEO) under the accession number GEO:
GSE34412.
Affymetrix gene expression analysis
For most xenograft lines, Affymetrix gene expression arrays
(U133 plus 2.0) were run on the ﬁrst or second transplant
generation (TG1 or TG2), and approximately every ﬁfth trans-
plant generation thereafter according to standard protocols
recommended by Affymetrix. Arrays were scanned on an
Affymetrix GeneChip 3000 Scanner (Agilent). Raw data were
then analyzed by ArrayAnalyzer (Insightful Corporation) for
normalization and expression estimation. All Affymetrix
microarray data have been deposited in GEO under the acces-
sion number GEO:GSE46106. An Affymetrix expression sum-
mary ﬁle is included as Supplementary Table S4. Sample
information for Affymetrix data are shown in Supplementary
Table S5 designated "affy.patient.info.ﬁnal.color" (Supplemen-
tary Tables S4 and S5 are available by download only from
www.bcxenograft.org).
Reverse-phase protein array expression analysis
Xenograft-derived tissuewas harvested and frozen at"80 &C
before use. Small pieces of tumor tissue were added to 2 mL
tubes with ceramic beads together with ice-cold lysis buffer
containing 1% Triton X-100, 50 mmol/L Hepes pH 7.4, 150
mmol/LNaCl, 1.5mmol/LMgCl2, 1mmol/L EGTA, 100mmol/L
NaF, 10 mmol/L NaPPi, 10% glycerol, and 1 mmol/L Na3VO4,
Complete Protease Inhibitor Cocktail and Phosphatase Inhib-
itor Cocktail (Roche Diagnostics). Protein supernatants were
isolated as described previously (26) and protein concentration
was determined by BCA assay (Pierce). Sampleswere diluted to
a uniformprotein concentration and thendenatured in 1%SDS
sample buffer for 5 minutes at 95&C. Samples were stored at
"80&C until use. Reverse-phase protein array (RPPA) analysis
was conducted as described previously (26, 27). Data were
obtained for 161 antibodies. A logarithmic value reﬂecting the
relative amount of each protein in each sample was generated
Table 1. Comparative xenograft take rate by transplant condition
Transplant
condition Host strain
Estradiol
pellet
Human
ﬁbroblasts
Number of
patients
Primary outgrowth
rate (%)
Stable xenograft
take rate (%)
1 Scid/Beige " " 38 18/38 (47.4) 1/38 (2.6)
2 Scid/Beige þ " 70 28/70 (40) 15/70 (21.4)
3 Scid/Beige þ þ 29 13/29 (44.8) 1/29 (3.4)
4 NSG þ " 32 10/32 (31.3) 6/32 (18.8)
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for analyses (28). Similarity of proteomic gene expression was
evaluated using cluster analysis as well as by Pearson distance
correlation analysis. An RPPA data summary is shown in
Supplementary Table S6. Sample information for the RPPA
data is shown in Supplementary Table S7, designated "rppa.
info.ﬁnal.color." Supplementary Tables S6 and S7 are available
by download only from www.bcxenograft.org.
Sequenom analysis
PCR and extension primers for each gene were designed
using Sequenom, Inc. Assay Design (Supplementary Table S8).
PCR-ampliﬁed DNA was cleaned using EXO-SAP (Sequenom)
primer extended by IPLEX chemistry, desalted using Clean
Resin (Sequenom), and spotted onto Spectrochip matrix chips
using a nanodispenser (Samsung). Chips were run in duplicate
on a Sequenom MassArray MALDI-TOF MassArray system.
Sequenom Typer Software and visual inspection were used to
interpret mass spectra. Reactions where 8% or more of the
resultant mass run in the mutant site in both directions were
scored as positive (Supplementary Table S9).
Metastasis rates
To evaluate metastatic behavior, lungs and liver were har-
vested from each host mouse at each transplant generation
and evaluated grossly and histologically by H&E staining (3
sections per sample; Table 2; Supplementary Table S10).
Xenograft treatment response
Fresh xenograft tumor fragments of selected xenograft lines
were transplanted into the cleared fat pad of recipient mice.
When tumors reached a volume of approximately 200 mm3,
mice were randomized and treated with either vehicle (9–10
mice), a single intraperitoneal injection of docetaxel (20mg/kg;
3–9 mice), a single intraperitoneal injection of doxorubicin (3
mg/kg; 3–9 mice), or combined trastuzumab and lapatinib (10
mice) as described (29, 30), depending on the treatment the
patient of origin received clinically. In some cases, patients
were treated with chemotherapy in combination with an
experimental targeted therapeutic (e.g., dasatinib or a gamma
secretase inhibitor). In such cases, resistance to both agents in
the patient and resistance to single agent in the xenograft were
considered concordant. Tumor size was monitored twice
weekly using calipers for a period of at least 2 weeks and
growth curves plotted. Sensitivity was deﬁned as 30% or more
regression [Response Evaluation Criteria in Solid Tumors
(RECIST) partial response or complete response]; resistance
was deﬁned as either less than 30% regression, stable disease,
or continued growth (RECIST stable disease or progressive
disease). Treatment responses in xenografts were compared
with those of the primary tumor for concordance, and statis-
tical signiﬁcance of the difference between observed and
expected concordance was evaluated by Fisher exact test. The
degree of concordance above that expected by chance was
evaluated using the kappa statistic.
Xenograft availability
Xenografts are available from the corresponding author for
academic/nonproﬁt use on a cost recovery basis via a Material
Transfer Agreement (mta@bcm.edu). Xenografts are main-
tained as viably frozen fragments (!1 mm3 frozen slowly at
"80&Cand stored in liquid nitrogen; shipped ondry ice). Frozen
fragments can be thawed rapidly and retransplanted. Frag-
ments grow somewhat slower in the ﬁrst transplantation after
freezing, but revert to their characteristic growth pattern in
subsequent transplant generations. All data presented in this
reportwere derived fromxenografts that had never been frozen.
Results
Establishment of xenografts using tumor fragments
Using SCID/Bg mice, 3 transplantation conditions were
tested (Table 1 and Supplementary Table S1). Under trans-
plantation condition 1 (unmanipulated hosts), primary tumor
fragments representing 38 unique patients were implanted to a
cleared fat pad to provide baseline take rates for comparison
with experimental conditions. Upon harvest, 18 primary out-
growths were found after histologic evaluation (!47% primary
outgrowth rate). Only one stably transplantable xenograft line
(BCM-2147) was established (2.6% stable take rate).
Under transplantation condition 2 (estradiol supplemen-
tation only), primary tumor fragments representing 70 unique
patients were implanted with 28 primary outgrowths obt-
ained (40% primary outgrowth rate; Table 1). Fifteen patients
yielded a stable xenograft (21.4% stable take rate), an approx-
imately 8-fold increase above baseline, and consistent with
recently published studies (1, 2, 5, 6, 8–12). Stable lines
represented 12 "triple-negative" patients (Table 2), as well
as 2 ER"PR"HER2þ patients (lines BCM-3143/3104 and
BCM-3963/4,169), and one ERþPRþHER2" patient (line
BCM-5097). Notably, 3 xenograft lines established under this
condition were generated from 2 BRCA1 mutation carriers
(patient 7, line BCM-3887; and patient 17, lines BCM-4913 and
BCM-5438), and one line was generated from a BRCA2 muta-
tion carrier (patient 19, line BCM-5097; Table 2).
In addition to these fragment transplant lines, under con-
dition 2 we also established a stable line from ascites cells from
one patient (BCM-3561). Ascites cells and the resulting xeno-
graft were triple negative, whereas the primary tumor in this
patient was ERþPRþ. We also established a line from one
ERþPR"HER2" patient (line BCM-4189) using ascites cells, as
well as one line from an ER"PR"HER2þ patient (line BCM-
3613), from cells derived from pleural effusion ﬂuid (Table 2).
Given the success of estradiol supplementation, we hypoth-
esized that addition of immortalized normal human ﬁbroblasts
would enhance the take rate further (as shown previously for
normal human mammary epithelium; 10). Under these condi-
tions (condition 3), primary and stable take rateswere similar to
those under condition 1 (Table 1), with 13 of 29 patients yielding
primary outgrowths (44.8%), but only 1 of 29 patients (3.4%)
yielding a stable xenograft line (line BCM-2665; Table 2). Thus,
rather than stimulating xenograft growth, the introduction of
humanﬁbroblasts derived fromanormal patientwas inhibitory
to stable, but not primary, outgrowth. It is currently unclearwhy
immortalized human ﬁbroblasts would stimulate growth of
normal humanmammary tissue, but inhibit estradiol-enhanced
growth of malignant tissue.
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Overall, we found no signiﬁcant differences in primary
outgrowth rates between transplantation conditions using
SCID/Bg host mice. However, there were signiﬁcant differ-
ences for stable outgrowth rates, with condition 2 yielding
more lines than condition 1 or 3 (OR: 11.0, 95% CI: 1.4–86.2, P¼
0.023; OR: 8.3, 95% CI:1.0–65.8, P ¼ 0.045, respectively).
Given that condition 2 (estradiol supplementation alone)
provided our best stable take rate in SCID/Bg mice, these
conditions were then tested in NOD/SCID/IL-2g-receptor null
(NSG) immunocompromised mice (condition 4; Table 1 and
Supplementary Table S1). Of 32 patients tested, 10 (31.3%)
yielded primary outgrowths, and 6 (18.8%) yielded stable
xenograft lines. These included 4 triple-negative lines (BCM-
4175, BCM-4195, BCM-4013, and BCM-5998), one ER"PR"
HER2þ line (BCM-4169), and one "triple-positive" ERþPRþ
HER2þ line (BCM-4888; Table 2). Primary outgrowth and stable
take rate in NSGmice were not statistically different from those
of SCID/Bgmice under condition 2 (logistic regression, P¼ 0.40
and P ¼ 0.64, respectively).
In total, 32 stably transplantable xenograft lines were estab-
lished representing 25 individual patients. Clinical features of
the patient and primary tumor of origin for each stable
xenograft line are shown in Table 2 and Supplementary Table
S1. Of note, we established pretreatment/posttreatment xeno-
graft pairs (BCM-2147/2,277; BCM-3611/3,824; BCM 3807/
4400; BCM 3963/4169; and BCM-4272/4849), from 5 patients.
With respect to ethnicity, we established xenografts represent-
ing 3 major ethnic groups, including 5 African American (AA)
patients, 13 Hispanic patients, and 7 non-Hispanic Caucasian
patients (Table 2). Finally, of the 22 patients used for fragment
transplant, 11 patients were lymph node positive with 9
patients being node negative (2 not reported). Also included
were 3 deﬁnitively metastatic patients (patients 23–25).
Regardless of the host strain used initially, all ER" lines were
propagated in the cleared fat pad of SCID/Bg mice without
humanizing ﬁbroblasts or estradiol after the third transplant
generation. All ERþ lines were propagated in the presence of
estradiol supplementation; their estrogen dependency and sen-
sitivity to hormonal therapies is currently under investigation.
Xenograft take rate versus patient clinical
characteristics
To ensure that the difference in stable take rate across the
transplantation conditionswas not due to differences in patient
characteristics, we compared across 4 different transplantation
conditions using Fisher exact test. Clinical characteristics of
patients were similar in the 4 groups used under the different
transplantation conditions (Supplementary Table S1).
To evaluate which clinical characteristics correlated with
high tumor take rate within each transplantation condition,
the primary and stable xenograft outgrowth rates were sum-
marized and compared across or between levels of each clinical
characteristic using Fisher exact test. Under condition 2, the
stable xenograft take rate was signiﬁcantly different between
grades I or II versus grade III invasive carcinoma, with only
grade III tumors yielding stably transplantable xenografts.
The stable take rate of ER" (!52%) and PR" (!37%) tumors
was signiﬁcantly higher than that of ERþ (!2%) and PRþ
(!3%) tumors, respectively. The rate of stable transplantation
across ethnic groups was not statistically different (Supple-
mentary Table S1).
Characteristics and stability of xenografts
To evaluate whether stable xenografts retained histologic
features and biomarker expression patterns consistent with
the tumor of origin, we conducted comparative histologic and
immunohistochemical analyses of outgrowths using clinically
relevant biomarkers (ER, PR, and HER2), as well as TP53 (p53),
EGFR(ErbB1), CK19, CK5, and Ki67, and compared biomarker
status with the tumor of origin (Table 2 and Supplementary
Table S3).
Figure 1 shows all xenograft lines for which matched pri-
mary patient samples were available for histologic comparison
(n ¼ 20; unmatched xenograft lines are shown in Supplemen-
tary Fig. S2). In all cases, patients retained their invasive
histologic phenotype as xenografts. Tumor cellularity was
estimated to exceed 80% in all xenografts (Fig. 1). Figure 2
shows 5 representative xenografts and their matched primary
breast cancer with respect to the range of biomarker expres-
sion observed (biomarker expression fully summarized in
Supplementary Table S3). Triple-negative xenografts could be
either CK19" (e.g., BCM-3807) or CK19þ (e.g., BCM-5156). All
ERþ and/or HER2þ xenografts generated were CK19þ. In all
cases that could be compared, each xenograft retained the
biomarker status observed in the patient. Furthermore, all lines
tested retained their histologic phenotype and biomarker
expression patterns of the tumor of origin over multiple
passages (3 representative xenografts are shown in Supple-
mentary Fig. S3). One xenograft (BCM-3807/4400) was found to
grow as a ﬂuid-ﬁlled mass at each transplant generation. The
presence of this yellowish ﬂuid was a clinical feature of the
tumor of origin in the patient.
Metastatic behavior of xenografts
Because 18 of the 32 xenograft lines were derived from 14
patients that were either lymph node positive, or had meta-
static breast cancer at other sites (brain, abdominal ascites,
pleural cavity; Table 2), we evaluated hostmice for the presence
of liver and lung metastases. Neither circulating tumor cells,
nor lymph node, brain or bone metastases, were examined in
this study. Lungs and livers of xenograft-bearing mice were
sampled at each transplant generation and screened by his-
tologic examination. In xenograft lines representing 12 of 25
patients (48%), stable xenograft lines (including 2 ERþ xeno-
graft lines) showed single or multiple foci of metastatic mam-
mary adenocarcinoma as pulmonary metastases (Fig. 3; Table
2 and Supplementary Table S10). No liver metastases were
detected. The presence of lung metastasis in mice did not
necessarily correlate with nodal/metastatic status in the
patient of origin (Table 2 and Supplementary Table S10).
Intrinsic subtype classiﬁcation
To determine the tumor subtype that these xenograft lines
best resemble, we conducted global gene expression analyses
using 244K human oligo microarrays (Agilent Technologies;
ref. 22). Using approximately 1,900 intrinsic gene list (24), we
Zhang et al.
Cancer Res; 73(15) August 1, 2013 Cancer Research4890
on January 25, 2016. © 2013 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst June 4, 2013; DOI: 10.1158/0008-5472.CAN-12-4081 
coclustered the xenografts samples with the UNC337 dataset
that has an appropriate representation of all the intrinsic
molecular subtypes (Luminal A, Luminal B, HER2-enriched,
Basal-like and Claudin-low; ref. 25). Xenografts clustered with
either the Basal-like or the HER2-enriched tumors and they did
not cluster as a single group (Fig. 4A and B). Interestingly, while
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representative patient biopsies
and their resulting xenografts.
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column; corresponding xenograft
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most (3 of 4) HER2þ samples clustered with the HER2-
enriched tumors, HER2þ BCM-3143/3104 line clustered with
the Basal-like tumors. Conversely, 3 HER2" xenografts (BCM-
4175, BCM-4189, and BCM-3561) were identiﬁed as HER2-
enriched. This observation is concordant with recent studies
in human tumors showing that not all HER2þ tumors are
HER2-enriched by gene expression, and that not all HER2-
enriched tumors are HER2þ (31). Regarding ERþ/HER2"
xenograft lines, BCM-4189 was identiﬁed as HER2-enriched
and BCM-5097 (also PRþ) was identiﬁed as Basal-like. This
observation is also concordant with a recent study showing
that a subset of poor prognosis ERþ tumors can be identiﬁed
as Basal-like (32). Finally, identical intrinsic subtype calls were
obtained when the PAM50 classiﬁer was applied to the
xenograft samples (Table 2).
Stability of xenografts with respect to their
transcriptome, proteome, and genome
To show whether transplantable xenografts were stable at
the transcriptome level, and to show whether xenografts
established using pretreatment biopsies were consistent
with xenografts established with posttreatment biopsies, we
conducted Affymetrix gene expression analysis using a
majority of the xenograft lines, with arrays conducted rough-
ly every ﬁfth transplant generation whenever available.
Within a given xenograft line, the transplant generations
invariably clustered together thus showing stability at the
level of gene expression across at least ﬁve transplant
generation (Fig. 5A). In addition, lines established from both
initial pretreatment fragments (I) as well as posttreatment
fragments (P) from the same patient also clustered together
(Fig. 5A). The within patient and between patients Pearson
correlation coefﬁcients are depicted in Fig. 5B showing the
within patient correlations to be consistently higher than the
between patients correlations.
To showwhether stably transplantable xenografts were also
stable at the proteome level, we conducted RPPA expression
analysis on xenografts representing all 25 patients using 161
antibodies. For those xenografts having samples representing
multiple transplant generations, the related samples invariably
clustered together thus showing stability at the level of the
proteome using both hierarchical clustering and Pearson
correlation coefﬁcient comparison methods (Fig. 5C and D).
In addition, lines established from both initial pretreatment
fragments (I) as well as posttreatment fragments (P) from the
same patient also invariably clustered together. As with the
Affymetrix analysis, within patient correlations were consis-
tently higher than between patient correlations.
To estimatewhether xenografts were genomically stable and
to identify single nucleotide polymorphisms (SNP) thatmay be
relevant to xenograft biology, we conducted Sequenom anal-
ysis of SNPs for 155 known polymorphisms in 32 cancer-
relevant genes (Supplementary Table S8) using each xenograft
line, with each line represented at multiple transplant genera-
tions whenever possible. No tumor suppressor genes were
evaluated in this study. A majority of the SNPs detected were
in the PIK3CA gene (lines BCM-3613, BCM-3807/4400, and
BCM-4888; Supplementary Table S9) each showing a unique
genetic alteration. However, a potentially activating SNP in c-
Met (N375S_A1124G) was identiﬁed in both BCM-2147/2277
and BCM-3143/3104, with BCM-2277 showing an additional
KRAS polymorphism (Q61LPR_A182TCG) relative to BCM-2147
BCM-3807 BCM-5156 BCM-3963 BCM-5097 BCM-4888
ER-α
PR
Ki67
K19
HER2
Figure 2. Biomarker expression in
representative xenografts. Five
representative patient samples
showing retained biomarker status
as xenografts. Xenograft line
designations are shown above the
column to which they apply.
Biomarker designations are shown
to the left of the row to which they
apply. Insets show the
corresponding biomarker
status in the tumor of origin.
Scale bar, 50 mm.
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that was either recovered as a function of sampling, or poten-
tially selected for, or acquired, as a function of AC treatment.
One activating AKT1 mutation (E17K_G49A) was identiﬁed in
BCM-4175. Thus, these transplantable xenograft lines are
genotypically stable across multiple transplant generations
with respect to the genes represented in this assay.
BC
M
-2
66
5
BC
M
-3
20
4
BC
M
-3
88
7
BC
M
-3
93
6
BC
M
-3
90
4
BC
M
-3
96
3
BC
M
-3
61
3
BC
M
-5
47
1
BC
M
-5
09
7
BC
M
-4
88
8
BC
M
-4
27
2
BC
M
-4
01
3
Figure 3. Histologic analysis of lung
metastases. Twelve xenograft lines
showing lung metastases are
shown. Insets show higher
magniﬁcation images of the
metastatic lesion. Scale
bar, 50 mm.
Biologically and Ethnically Diverse Breast Cancer Xenografts
www.aacrjournals.org Cancer Res; 73(15) August 1, 2013 4893
on January 25, 2016. © 2013 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst June 4, 2013; DOI: 10.1158/0008-5472.CAN-12-4081 
Patient/xenograft treatment response concordance
To evaluate biologic relevance and translational use, we
tested treatment responses of 11 xenograft lines derived from
patients for whom we have a total of 13 observed clinical
treatment responses to essentially the same drug. Twelve of 13
xenograft responses matched the corresponding clinical
responses (Supplementary Table S11; Supplementary Fig.
S4). The sole discordant result was in a xenograft line derived
from ascites. The ascites cells were resistant to paclitaxel in the
patient, but were modestly sensitive to docetaxel when grown
as a xenograft (33% decrease in tumor volume over the
observation period). As most xenograft lines were resistant to
the therapies used, one would expect about 60% concordance
entirely by chance. However, our observed concordance of 92%
was substantially higher (k ¼ 0.75, P¼ 0.003), and there was a
signiﬁcant association between the xenograft and patient-
derived results (Fisher exact test, P ¼ 0.04)
Discussion
The mouse mammary gland model derives its experimental
power, in part, from the ability to transplant mammary epi-
thelium from one animal to another. Transplantation allows
one to expand normal, genetically modiﬁed, or neoplastic
tissue into multiple hosts. With respect to therapeutic studies,
tissue expansion by transplantation allows study of the in vivo
effects of multiple agents on the behavior of the epithelium. In
contrast, such studies are not possible in human patients, and
experimental analysis of the human mammary gland and
breast cancers has been limited by the lack of a suitable
transplantation model in which malignant xenografts grow
efﬁciently and tumor biology is, to the extent possible, faithful
to the biology of the tumor of origin in the patient. In this study,
we show that the SCID/Bg and NSG immunocompromised
mice are relatively permissive for growth of malignant tissue
and allow the establishment of stably transplantable "triple-
negative" HER2þ and ERþ xenograft lines from an ethnically
diverse patient population. These xenografts are histologically
and immunohistochemically indistinguishable from the tumor
of origin, show comparable treatment responses, and are
transcriptionally, translationally, posttranslationally, and gen-
omically, stable across multiple transplantation generations.
There have been numerous attempts to generate transplant-
able xenografts over the last 3 decades. Historically, stable take
rates for xenografts were low (!10%, or less), but have
improved in more recent studies (1, 2, 5, 6, 8–10, 33–40). Our
stable take rate under condition 2 (estradiol supplementation
in SCID/Bg mice) was approximately 21%, with a statistically
similar take rate observed in NSG mice (!19%). Thus, the rate
we obtained in SCID/Bg and NSGmice is at the high end of the
historical range. Similarly, high per patient take rates (10 of 42
patients; !24%) were shown recently by DeRose and collea-
gues (12) using tissue fragments coated in Matrigel and
implanted into the epithelium-free fat pad of NOD/SCID mice
supplemented with estradiol. An exceptionally high take rate
was also obtained by Kabos and colleagues (10 of 27 patients;
37%; ref. 15) using tissue fragments or metastatic cells (pleural
ﬂuid/ascites) coated in Matrigel and implanted into the intact
fat pad of either NOD/SCID or NSG mice supplemented with
estradiol. Elevated take rates in advanced tumors in our studies
are consistent with the apparent elevated tumor-initiating
cell (TIC; also known as cancer stem cell) frequency in high-
grade tumors relative to low-grade tumors (41). However, these
data could also be explained by lack of one or more factors
required for growth of low-grade tumors in the SCID/Bg and
NSG mice rather than a decreased TIC frequency per se. Our
data are also consistent with these recent studies showing that
estradiol supplementation stimulates growth of breast cancer
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xenografts, including ER" xenografts (12, 15, 42, 43). This
stimulatory effect of estradiol supplementation on ER-negative
tumor growth is, at least in part, due to an ERa-mediated effect
on bone marrow-derived myeloid cells that promote angio-
genesis and tumor growth (44).
Despite the observation that approximately 80% of all breast
cancers in women are ERþ, relatively few cell line or xenograft
models are available. Recently, a few groups have succeeded in
generating ERþ xenografts lines (12, 15). In this work, we were
also able to generate 3 new stably transplantable ERþ xeno-
graft lines, 2 of which are metastatic to the mouse lung.
Unfortunately, the rate of stable outgrowth was still low
relative to triple-negative tumors, and perhaps due to the
omission of Matrigel coating in our protocol, we did not
recover stable lines representing the luminal subtypes. Thus,
efﬁcient establishment of ERþ xenografts will require further
optimization. One potential method is via cotransplantation
with mesenchymal stem cells, which were shown recently to
enhance mammosphere formation in vitro (45), and to stim-
ulate growth and metastasis of established xenografts in vivo
(12, 46–48). Alternatively, some mouse proteins [e.g. prolactin,
hepatocyte growth factor, interleukin (IL)-6] do not activate
their human receptor counterparts (48–50). Thus, tissue-
appropriate expression of one or more of these human ligands
as transgenes in an immunocompromised mouse background
may be necessary to stimulate ERþ xenograft growth fully.
Two important features of a useful experimental model are
the degree to which the experimental model faithfully recapi-
tulates the tumor in the patient of origin and the stability of the
experimental model over time. In this study, all xenografts
showed biologic consistency with the tumor of origin both at
the level of histology, and with respect to several clinically (ER,
PR, HER2, Ki67) and biologically (TP53, EGFR, CK5/6, CK19)
relevant biomarkers. With respect to the issue of stability over
time, all xenografts for which Affymetrix RNA expression
patterns or RPPAprotein expression patternswere determined
for multiple transplantation generations showed a high degree
of stability with respect to gene expression at the mRNA and
protein level, including posttranslationalmodiﬁcations. Unfor-
tunately, it was not possible to evaluate the degree towhich the
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Figure 5. Transcriptome and proteome stability. Xenograft lines are phenotypically stable over multiple transplant generations with respect to gene
expression by Affymetrix microarray and RPPA. A, hierarchical cluster analysis using all probesets with detectable expression. Xenograft designation
(BCM-####), and transplant generation number (TG#) are shown for each branch of the dendrogram. Patient of origin/xenograft association is designated by
color. B, box and whisker plot of Pearson correlation distances within patient and between patients. C, hierarchical cluster analysis using 161 antibodies in
RPPA. Xenograft designations are as shown in A. D, box and whisker plot of Pearson correlation distances within patient and between patients.
Biologically and Ethnically Diverse Breast Cancer Xenografts
www.aacrjournals.org Cancer Res; 73(15) August 1, 2013 4895
on January 25, 2016. © 2013 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst June 4, 2013; DOI: 10.1158/0008-5472.CAN-12-4081 
xenograft transcriptome or proteome were consistent with
those of the tumor of origin because patients were enrolled in
ongoing clinical trials and their array data could not yet be
released, and remaining banked tissuewas not sufﬁcient to run
RPPA without exhausting the sample entirely.
In addition to the molecular diversity shown by this collec-
tion of xenografts, the lines established represent diversitywith
respect to the ethnic groups, as well as metastatic behavior. Of
particular interest is theﬁnding the 2 of the 3 ERþbreast cancer
xenografts established were metastatic from the orthotopic
site. Similar results were recently obtained by DeRose and
colleagues (12). In contrast, we know of only one ERþ metas-
tasis model in cell lines, a metastatic derivative of MCF7
developed recently (51). Thus, these models should be useful
in evaluating ethnic differences in tumor behavior, as well as
evaluating therapeutic agents that might inﬂuence metastatic
behavior, particularly of ERþ breast cancer.
Perhaps, the most critical issue not addressed fully to date is
the question of whether PDX models respond to a given
treatment in a manner similar to the tumor of origin in the
patient. This issue is important not only to establish relevance
as experimental models, but particularly from a clinical/trans-
lational standpoint. If, in fact, the PDXmodels respond similarly
to a given agent, it should be possible to identify predictive
indicators of response that may ultimately be useful clinically.
Furthermore, there should be relevant biologic underlying PDX
treatment resistance that can be exploited to improve treat-
ment clinically. A previous study evaluating 7 xenografts
showed an observed concordance of 71% versus an expected
concordance of 47% (9). However, statistical signiﬁcance was
not showed using this sample size (k ¼ 0.46, P ¼ 0.08). In our
study, a majority of xenograft lines tested showed qualitatively
identical treatment responses as the corresponding patient
treated with a similar or identical agent, and statistical signif-
icance was achieved using this increased sample size.While the
lack of a functional immune systemmay ultimately be shown to
alter treatment responses to some agents, the observation that
xenograft lines responded to 2 commonchemotherapeutics in a
qualitatively identical manner as the patient of origin strongly
suggests that results obtained in "mouse clinical trials" will be
generally relevant to patients.
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